174 related articles for article (PubMed ID: 30519392)
1. TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2.
Xu C; Guo Y; Liu H; Chen G; Yan Y; Liu T
Cell Biosci; 2018; 8():61. PubMed ID: 30519392
[TBL] [Abstract][Full Text] [Related]
2. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
Li Q; Song W; Wang J
Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
[TBL] [Abstract][Full Text] [Related]
3. HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2.
Ye Y; Yang S; Han Y; Sun J; Xv L; Wu L; Ming L
Open Biol; 2019 Sep; 9(9):190068. PubMed ID: 31551012
[TBL] [Abstract][Full Text] [Related]
4. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
Zhang Z; Xiong R; Li C; Xu M; Guo M
Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2.
Wu Y; Hu L; Liang Y; Li J; Wang K; Chen X; Meng H; Guan X; Yang K; Bai Y
Mol Cancer; 2017 Aug; 16(1):150. PubMed ID: 28854977
[TBL] [Abstract][Full Text] [Related]
6. EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression.
Wang C; Li X; Zhang J; Ge Z; Chen H; Hu J
Onco Targets Ther; 2018; 11():7853-7864. PubMed ID: 30464532
[TBL] [Abstract][Full Text] [Related]
7. lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer.
Yu G; Zhou H; Yao W; Meng L; Lang B
Mol Ther Nucleic Acids; 2019 Jun; 16():257-271. PubMed ID: 30925453
[TBL] [Abstract][Full Text] [Related]
8. Long Non-Coding RNA Taurine Upregulated Gene 1 (TUG1) Downregulation Constrains Cell Proliferation and Invasion through Regulating Cell Division Cycle 42 (CDC42) Expression Via MiR-498 in Esophageal Squamous Cell Carcinoma Cells.
Wang Z; Liu J; Wang R; Wang Q; Liang R; Tang J
Med Sci Monit; 2020 Mar; 26():e919714. PubMed ID: 32139664
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4.
Yang C; Shen S; Zheng X; Ye K; Ge H; Sun Y; Lu Y
FASEB J; 2020 May; 34(5):6055-6069. PubMed ID: 32239565
[TBL] [Abstract][Full Text] [Related]
10. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis.
Chang N; Ge N; Zhao Y; Yang L; Qin W; Cui Y
J Clin Lab Anal; 2022 May; 36(5):e24304. PubMed ID: 35312115
[TBL] [Abstract][Full Text] [Related]
11. LncRNA TUG1 contributes to ESCC progression via regulating miR-148a-3p/MCL-1/Wnt/β-catenin axis in vitro.
Tang Y; Yang P; Zhu Y; Su Y
Thorac Cancer; 2020 Jan; 11(1):82-94. PubMed ID: 31742924
[TBL] [Abstract][Full Text] [Related]
12. LncRNA TUG1 promotes tumor growth and metastasis of esophageal squamous cell carcinoma by regulating XBP1 via competitively binding to miR-498.
Jin G; Yang Y; Tuo G; Wang W; Zhu Z
Neoplasma; 2020 Jul; 67(4):751-761. PubMed ID: 32305055
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma.
Cheng J; Zhang R; Yan M; Li Y
BMC Cancer; 2022 Mar; 22(1):238. PubMed ID: 35241028
[TBL] [Abstract][Full Text] [Related]
14. High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma.
Jiang L; Wang W; Li G; Sun C; Ren Z; Sheng H; Gao H; Wang C; Yu H
Cancer Chemother Pharmacol; 2016 Aug; 78(2):333-9. PubMed ID: 27329359
[TBL] [Abstract][Full Text] [Related]
15. C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
Shi H; Mao Y; Ju Q; Wu Y; Bai W; Wang P; Zhang Y; Jiang M
Int J Oncol; 2018 Jul; 53(1):167-176. PubMed ID: 29658564
[TBL] [Abstract][Full Text] [Related]
16. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma.
Xu Y; Wang J; Qiu M; Xu L; Li M; Jiang F; Yin R; Xu L
Tumour Biol; 2015 Mar; 36(3):1643-51. PubMed ID: 25366138
[TBL] [Abstract][Full Text] [Related]
18. Low expression of TUG1 promotes cisplatin sensitivity in cervical cancer by activating the MAPK pathway.
Wei X; Zhou Y; Qiu J; Wang X; Xia Y; Sui L
J BUON; 2019; 24(3):1020-1026. PubMed ID: 31424656
[TBL] [Abstract][Full Text] [Related]
19. LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression.
Hu D; Ma A; Lu H; Gao Z; Yu Y; Fan J; Liu S; Wang Y; Zhang M
Appl Biochem Biotechnol; 2024 Mar; ():. PubMed ID: 38507172
[TBL] [Abstract][Full Text] [Related]
20. Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling.
Zhou Q; Hu T; Xu Y
J Drug Target; 2020 Feb; 28(2):204-211. PubMed ID: 31305159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
